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ABSTRACT: 
Background: Testicular cancer survivors (TCS) are at significantly increased risk for 
cardiovascular disease (CVD), with metabolic syndrome (MetS) an established risk 
factor. No study has addressed clinical and genetic MetS risk factors in North American 
TCS. 
 
Patients and Methods: TCS were <55 years at diagnosis and received first-line 
chemotherapy. Patients underwent physical examination, and had lipid panels, 
testosterone, and soluble cell adhesion molecule-1 (sICAM-1) evaluated. A SNP in 
rs523349 (5-α-reductase gene, SRD5A2), recently implicated in MetS risk, was 
genotyped. Using standard criteria, MetS was defined as ≥3 of the following: 
hypertension, abdominal obesity, hypertriglyceridemia, decreased high-density 
lipoprotein (HDL), and diabetes. Matched controls derived from the National Health and 
Nutrition Examination Survey. 
 
Results: We evaluated 486 TCS (median age: 38.1 years). TCS had a higher 
prevalence of hypertension versus controls (43.2% vs. 30.7%, P<.001), but were less 
likely to have decreased HDL (23.7% vs. 34.8%, P<.001) or abdominal obesity (28.2% 
vs. 40.1%, P<.001). Overall MetS frequency was similar (21.0% and 22.4%, P=.59), did 
not differ by treatment (P=.20), and was not related to rs523349 (P=.61). For other CVD 
risk factors, TCS were significantly more likely to have elevated low-density lipoprotein 
(LDL) (17.7% vs. 9.3%, P<.001), total cholesterol (26.3% vs 11.1%, P<.001), and body 
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mass index ≥25 kg/m2 (75.1% vs. 69.1%, P=.04). In multivariate analysis, age at 
evaluation (P<.001), testosterone ≤3.0 ng/mL (OR=2.06, P=.005), and elevated sICAM-
1 (ORhighest vs. lowest quartile=3.58, P=.001) were significantly associated with MetS.  
 
Discussion: Metabolic abnormalities in TCS are characterized by hypertension, 
increased LDL and total cholesterol, but lower rates of decreased HDL and abdominal 
obesity signifying possible shifts in fat distribution and fat metabolism. These changes 
are accompanied by hypogonadism and inflammation. 
 
Conclusion: TCS have high prevalence of CVD risk factors that may not be entirely 
captured by standard MetS criteria. Cancer treatment-associated MetS requires further 
characterization. 
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1. INTRODUCTION 
Testicular cancer (TC) is the most common cancer among men aged 18 to 39 
years, with increasing incidence over the past 20 years.1 With cisplatin-based 
chemotherapy, patients with metastatic disease have achieved unprecedented survival 
rates,2 with cure expected in 80%.3 Overall, the 5-year relative survival rate for all TC 
patients is 95%.4 As a result, 1 in 600 men in the U.S. is now a TC survivor (TCS), 5 with 
a gain of upwards of 40 years of life.6 Thus, TCS comprise a unique population in which 
to study the long-term adverse effects of cancer treatment in adult-onset cancer 
survivors.7 In particular, TCS given chemotherapy experience up to 7-fold increased 
long-term risks for cardiovascular disease (CVD) compared to controls.8-13  
In the general population, metabolic syndrome (MetS) is a major risk factor for 
CVD.14 MetS is a constellation of interrelated CVD risk factors, including insulin-
resistance, hypertension, elevated triglyceride levels, decreased high-density lipoprotein 
(HDL) levels, and obesity.14 Using various definitions, European studies of TCS have 
reported a wide variation in the prevalence of MetS, ranging from 13%-39%.15-19 Some 
investigations have demonstrated MetS risk to be higher among TCS compared to 
controls,15-18 but others have not.19 Boer et al.20 reported MetS to be more prevalent in 
TCS carrying the minor allele of a single nucleotide polymorphism (SNP), rs523349 
(V89L), compared to wild type (33% vs. 19%, P=.032). This SNP is a nonsynonymous 
coding variant in the gene SRD5A2, encoding steroid 5-α-reductase type II. The 
prevalence of MetS was particularly high (66.7%) in TCS who had low testosterone 
levels (<4.3 ng/mL) and carried a minor allele (homozygous or heterozygous) genotype. 
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Given the conflicting data on MetS prevalence in European studies of TCS and 
the lack of information in North American patients, we evaluated for the first time MetS 
and associated risk factors among a large cohort of North American TCS.21 We also 
examined the reported association of the rs523349 SNP with MetS in our patients. 
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2. PATIENTS AND METHODS 
2.1 Participants 
The Platinum Study evaluates the late consequences of platinum-based 
chemotherapy and was approved by Institutional Review Boards at all participating 
institutions.21,22 Each participant provided written informed consent allowing access to 
medical records since cancer diagnosis. Eligibility criteria included: diagnosis of germ 
cell tumor (GCT) at age <55 years; treatment with first-line platinum-based 
chemotherapy, no salvage chemotherapy, no radiotherapy, and no antecedent 
chemotherapy for another primary cancer. All participants were disease-free at the time 
of clinical evaluation. We included in this analysis all TCS for whom blood samples had 
been analyzed and who had complete data on all MetS components. 
 
2.2 Assessments 
2.2.1 Socio-demographic, lifestyle, and behavioral factors. TCS completed a 
questionnaire regarding health outcomes, lifestyle behaviors and current prescription 
medications (including antihypertensive, diabetic and lipid-lowering medications). 
Demographic information included age at cancer diagnosis and clinical evaluation, race, 
education, employment and marital status. Smoking status was categorized as current, 
former, or never smoker. Physical activity was reported as the average time per week 
engaged in various forms of exercise.23 Moderate- and vigorous-intensity physical 
activity were defined as participating in at least one activity per week with a metabolic 
equivalent (MET) of 3 to <6 METs or ≥6 METs, respectively.24,25  
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2.2.2 Data collection from medical records. Study staff abstracted data 
according to a uniform protocol, using forms adapted from a prior study.22 Data included 
date of GCT diagnosis, histology and site of GCT, and for each cytotoxic drug: name, 
dose, date(s) of administration, number of cycles, and cumulative dose. All data were 
entered into the eClinical system,26 supported by the study coordinating center. 
2.2.3 Clinical evaluation. TCS underwent a physical examination measuring 
height, weight, and waist circumference. Body mass index (BMI) was calculated as 
kg/m2. Blood pressure was measured twice after resting for 5 minutes and averaged. 
Blood samples were drawn and time of last meal was recorded. Blood samples were 
frozen and shipped to the central laboratory. Serum levels of testosterone, luteinizing 
hormone (LH), lipids, creatinine; and soluble cell adhesion molecule-1 (sICAM-1), a 
known CVD biomarker,27-29 were measured using commercial assays. Hypogonadism 
was defined using the U.S. Food and Drug Administration definition (total serum 
testosterone ≤3.0 ng/mL),30 which is commonly used in clinical practice.  
2.2.4 DNA genotyping and imputation. DNA was extracted from blood samples 
collected at clinical evaluation. SNPs were genotyped on the Illumina 
HumanOmniExpressExome chip (Illumina, San Diego) at the RIKEN Center for 
Integrative Medical Science (Yokohama, Japan). Because the SNP of interest is not 
called on this chip, we performed genotype imputation following standard quality control 
measures as previously described.31 Imputation was performed on the University of 
Michigan Imputation Server32 with the following parameters: 1000G Phase 1 v3 Shapet2 
(no singletons) reference panel, SHAPEIT phasing, and the EUR (European) 
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population. Linkage Disequilibrium (LD) structures around the variant of interest were 
determined using NIH’s LDLink33 using the CEU (European) population. 
 
2.3 Definition of MetS 
MetS was defined using a modification of the National Cholesterol Education 
Program’s Adult Treatment Panel III (NCEP ATP III) Guidelines14 as the presence of ≥3 
of the following (Table 1): 1) systolic blood pressure ≥130 mmHg and/or diastolic blood 
pressure ≥85 mmHg or use of antihypertensive medication; 2) abdominal obesity (waist 
circumference ≥102 cm); 3) self-reported diabetes and medication use; 4) HDL 
cholesterol <40 mg/dL or lipid-lowering medication; and 5) serum triglyceride level ≥150 
mg/dL (fasting) or ≥175 mg/dL (non-fasting). These MetS critera were developed by 
several major organizations to represent one harmonized definition.14 Criteria for HDL 
and triglyceride cut-points were adapted from recent guidelines.34 
 
2.4 Control group 
Matched controls for selected comparisons were chosen from the National 
Health and Nutrition Examination Survey (NHANES) using two consecutive data sets 
(2011-2012 and 2013-2014), following methods applied by the St. Jude’s Lifetime 
Cohort.35 Controls (restricted to men without cancer) were matched 1:1 on race, age 
(within 5-years), and educational level. 
 
2.5 Statistical analyses 
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Data were summarized with median (ranges) for continuous variables and 
proportions for categorical variables in two TCS subgroups defined by the presence or 
absence of MetS. The two groups were compared using the Pearson chi-square and 
two-sided Wilcoxon Rank Sum tests on categorical and continuous variables, 
respectively. TCS were compared to controls using the Pearson chi-square test with 
regard to the prevalence of various MetS components, as well as other CVD risk factors 
not included in the NCEP ATP III criteria. A composite score was calculated based on 
the cut-points for the individual MetS components, with a range of 0-5; zero indicated no 
abnormal components. Based on MetS diagnostic criteria,14 participants with a 
composite score of 3-5 were classified with MetS. 
To determine factors associated with MetS in TCS, a two-step approach was 
used. First, logistic regression models were used to estimate the odds ratios (OR), 95% 
confidence intervals (CI) and P-values for all clinical, demographic, behavioral, and 
laboratory measures. Second, factors that were significantly associated with MetS in 
univariate analyses were included in the multivariable model. All statistical analyses 
were conducted using SAS version 9.4. All tests were two-sided, with P-values <.05 
considered statistically significant. 
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3. RESULTS 
3.1 TCS characteristics. Median time from chemotherapy completion to study 
enrollment was 4.7 years (range=0.4-23.9) (Table 2). TCS with MetS (n=102) were 
significantly older at clinical evaluation compared to those without MetS (n=384) 
(median 44.4 vs. 36.6 years, P<.001). TCS received either bleomycin, etoposide and 
cisplatin (BEP) (54.7%) or etoposide and cisplatin (EP) (33.1%), but MetS prevalence 
did not differ by treatment regimen nor by cumulative dose of cisplatin or bleomycin. 
TCS with MetS had a significantly higher prevalence of obesity (60.8% vs. 22.7%, 
P<.001), hypogonadism (46.1% vs. 26.8%, P<.001), and elevated sICAM levels 
compared to those without MetS (Table 3).  
 
3.2 Comparison with matched controls. TCS were more likely to have 
hypertension (43.2% vs. 30.7%, P<.001), but less likely to have low HDL (23.7% vs. 
34.8%, P<.001) and abdominal obesity (28.2% vs. 40.1%, P<.001) compared to 
controls (Table 4). Although overall MetS prevalence in TCS and controls was 
comparable (21.0% vs. 22.4%, P=.59), there were significant differences in other CVD 
risk factors not included in the NCEP ATP III definition. TCS were more likely to have 
elevated LDL ≥160 mg/dL (17.7% vs. 9.3%, P<.001), total cholesterol ≥240 mg/dL 
(26.3% vs. 11.1%, P<.001), and BMI ≥25 kg/m2 (75.1% vs. 69.1%, P=.04). Also, a 
larger proportion of TCS than controls reported participating in moderate- (93.8% vs 
42.4%, P<.001) or vigorous-intensity physical activity (66.7% vs. 33.5%, P<.001), and 
were less likely to be current smokers (9.3% vs. 25.9%, P<.001). 
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3.3. Factors associated with MetS in TCS. Results of univariate analysis of 
factors potentially associated with MetS are shown in Table 5. Factors statistically 
significant on univariate analysis were incorporated into a multivariate model, in which 
age, low serum testosterone and sICAM remained significantly associated with MetS 
(Table 6). For every 10-year increase in age at clinical evaluation, MetS risk increased 
by 1.7-fold (95% CI=1.33-2.30, P<.001). Testosterone level ≤3.0 ng/mL was associated 
with a significant two-fold increased risk of MetS compared with higher levels (P=.005). 
MetS risk increased monotonically with increasing sICAM level (OR=3.58 comparing 
highest vs. lowest quartile, P=.001). Educational level, marital status, alcohol intake and 
vigorous-intensity physical activity were not associated with MetS risk in the multivariate 
model. 
 
3.4 Genetic Association of MetS with SRD5A2. The SNP rs523349 showed 
high imputation quality (R2=1), call rate (>0.99) and perfect Hardy-Weinberg equilibrium 
(P=1.0). This imputed SNP was in perfect LD with a nearby genotyped SNP, 
rs12467911. LDLink revealed that the expected LD R2 in a European population is 
0.975. Genotype frequencies by MetS status are presented in Table 7. The variant 
genotype did not correlate with MetS (P=.61). 
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4. DISCUSSION 
Our investigation represents the largest to date to address the prevalence of 
metabolic abnormalities in TCS treated with contemporary platinum-based regimens 
and is the only investigation of North American patients. At a median age of only 38 
years, three in four TCS were overweight or obese, 43% had hypertension, and a 
significantly higher proportion had elevated LDL or total cholesterol than did matched 
controls. Overall, one in five TCS had MetS according to the NCEP ATP III definition.14 
There was no difference in the prevalence of MetS by treatment regimen (BEP vs. EP) 
nor by cumulative dose of cisplatin or bleomycin. Significant risk factors for MetS 
included hypogonadism, increasing age and increasing level of sICAM. No association 
with MetS was observed with the variant genotype for rs523349. 
Westerink et al. recently pointed out that the etiology of cancer treatment-induced 
metabolic syndrome (CTI-MetS) differs from MetS in the general population,36 where 
sedentary lifestyle, along with excess caloric intake, are the primary causes.14 In 
contrast, CTI-MetS is multifactorial and differs by cancer diagnosis, treatment and 
patient characteristics. Surgery,37,38 radiotherapy,39 chemotherapy18,19,40 and hormonal 
therapy41-45 have each been shown to induce CTI-MetS. In TCS, hypogonadism and 
chemotherapy rather than sedentary behavior are likely the main causes for metabolic 
abnormalities. Our TCS were at least twice more likely than controls to engage in 
moderate or vigorous-intensity physical activity. Despite this, we did not find a 
significant difference in the prevalence of MetS between TCS and NHANES controls, 
likely because MetS criteria originally developed for the general population14 do not 
reflect the full spectrum of metabolic abnormalities seen in TCS. 
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The relationships between hypogonadism with MetS and CVD in the general 
population46-51 and TCS13,16-19 are well-established. In our study, about one third of 
survivors were hypogonadal, which is higher than reported in the general population,52 
but not unexpected since our participants had undergone orchiectomy. In our cohort, 
TCS with hypogonadism were twice as likely to have MetS in multivariate analysis. 
Hypogonadism also correlated with obesity, hypertension, high LDL and total 
cholesterol in univariate analysis (data not shown). Hypogonadism may also explain the 
lower prevalence of low HDL in TCS compared to controls as androgens can have a 
suppressive effect on HDL.53 In addition, the smaller waist circumference in TCS 
compared to controls while having a higher BMI may be explained by increased femoral 
adipose tissue deposition observed in hypogonadal compared with eugonadal 
patients.54  
Studies of the effect of testosterone replacement on MetS and CVD risk in TCS 
are sparse. While such investigations in older men in the general population showed 
favorable effects on lipid metabolism, bone mineral density, muscle mass, and fat-free 
body mass,55,56 the effects of testosterone replacement on CVD risk have been 
conflicting.57 One clinical trial showed an excess of CVD adverse events in older men 
treated with testosterone compared with placebo,58 but another trial in a similar 
population did not.59 However, these findings may not apply to young and physically 
active TCS. For young TCS with symptomatic hypogonadism, testosterone replacement 
should be considered, and future research is needed to address both the benefits and 
risks of testosterone replacement therapy. 
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Inflammation is considered a critical pathogenic component of atherosclerosis.60 
de Haas et al. provided a comprehensive assessment of pro-inflammatory markers in 
chemotherapy-treated TCS, finding significantly elevated levels of several markers in 
patients with MetS vs. those without MetS.17 Herein, we found that sICAM levels 
increased with increasing MetS risk even after adjustment for age and additional risk 
factors in multivariate analysis. sICAM is an adhesion molecule that serves a critical role 
in the adhesion and transmigration of leucocytes across the endothelial wall, an early 
step in the formation of the atherosclerotic plaque.61 Epidemiological studies have 
shown strong, positive associations between sICAM levels and future CVD events in 
apparently healthy men and women.27-29 Vaughn et al. reported sICAM levels to be 
higher in TCS treated with chemotherapy than surgery only, suggesting a direct 
mechanism for CVD through chemotherapy-induced endothelial dysfunction.62 In vitro 
studies further support this hypothesis.63-65  
There has been increasing interest in personalizing care for cancer survivors. 
One approach is to identify genetic variants that can predispose survivors to selected 
adverse health outcomes.7 In this study, we evaluated a SNP (rs523349) in the steroid 
5-α-reductase type II gene recently associated with MetS in TCS.20 This SNP decreases 
enzyme activity and thus the conversion of testosterone to the more active metabolite 
dihydrotestosterone.66 The frequencies of the wild type and variant rs523349 in our 
cohort were comparable to those in Boer et al20 (Table 7); however, in our cohort with 
more than twice the sample size, we found no association with MetS. An approach that 
accounts for multiple genes involved in relevant pathways may better identify clinically 
actionable results that could inform risk-adapted management approaches. 
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The prevalence of MetS in our patients is within the range (17%–41%) reported 
in European studies of platinum-treated TCS (summarized in Table 8).13,15-19 Although 
each European series used slightly different criteria for MetS than applied here, it is still 
possible to compare the prevalence of individual MetS components. The most 
pronounced component of MetS among our TCS was hypertension (43%). Haugnes et 
al19 found significantly increased risks of hypertension in cisplatin-treated patients 
compared with surgically treated patients (≥45% vs. 34%) as did Willemse et al18 (31% 
vs. 14%). The association between cisplatin-based chemotherapy, hypertension, and 
CVD in TCS is well-established, and has been reviewed elsewhere.7,65  
 
Strengths and limitations: 
Strengths of our study include the large number of patients, detailed medical 
chart abstraction, and use of contemporary and homogeneous platinum-based 
chemotherapy regimens. We used a definition for hypogonadism that is clinically-
relevant and easily applicable to clinical practice. 
However, any cross-sectional design has potential limitations and does not allow 
us to infer causation of evaluated risk factors to MetS, although prospective data 
collection is planned for this cohort. Also, the SNP of interest was imputed and not 
genotyped, although it was in perfect LD with a nearby genotyped SNP. Our participants 
also represent for the most part well-educated TCS followed at major academic 
institutions and the prevalence of MetS may be higher in community-based settings. 
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Moreover, participants in the population-based NHANES cohort may not be comparable 
to our TCS in terms of all relevant sociodemographic and lifestyle variables. 
Conclusion and recommendations: 
There is a high prevalence of metabolic abnormalities in TCS treated with 
chemotherapy at a relatively young age and shortly after completion of cancer 
treatment. The etiology of MetS in cancer survivors likely differs from the general 
population,36 thus, applying criteria developed for the general population to cancer 
survivors may underestimate CVD risk. Importantly, longitudinal cohort studies of 
survivors are needed to develop more accurate risk prediction models for CVD. 
Meanwhile, it is reasonable to assume that management strategies for components of 
MetS may have similar positive effects on CVD prevention. Providers are encouraged to 
screen and adequately treat TCS for hypertension, dyslipidemia and hypogonadism. 
Further, all TCS should be encouraged to adopt practices consistent with a healthy 
lifestyle, including maintenance of ideal body weight, avoidance of tobacco use and 
engagement in regular exercise. 
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Table 1: Criteria Used to Define Metabolic Syndrome (MetS) 
Measure AHA/NHLBI modified NCEP ATPIII 
criteria for MetS14 
Definition used for current study 
Elevated blood 
pressure 
BPsystolic ≥130 mmHg 
and/or 
BPdiastolic ≥85 mmHg 
or 
Drug treatment for hypertension 
BPsystolic ≥130 mmHg 
and/or 
BPdiastolic ≥85 mmHg 
or 
Drug treatment for hypertension* 
Elevated waist 
circumference 
Population- and country-specific 
definitions: 
 
U.S. ≥102 cm in men 
≥102 cm 
Elevated fasting 
glucose 
≥100 mg/dL Self-reported diabetes 
and 
Taking drug treatment for diabetes† 
Reduced HDL <40 mg/dL in males; 
or 
Drug treatment for reduced HDL 
<40 mg/dL 
or 
Drug treatment for reduced HDL 
(including statins, fibrates and nicotinic 
acid)‡ 
Elevated 
triglycerides 
≥150 mg/dL 
or 
Drug treatment for elevated 
triglycerides 
≥150 mg/dL (fasting) 
or 
≥175 mg/dL (non-fasting)‡ 
or 
Drug treatment for elevated 
triglycerides§ 
Metabolic syndrome ≥3 criteria ≥3 criteria 
Abbreviations: AHA/NHLBI = American Heart Association/National Heart Lung Blood Institute BP = blood 
pressure; HDL = High density lipoprotein cholesterol; NCEP ATP III = National Cholesterol Education 
Program’s Adult Treatment Panel III 
 
* Study participants were asked “Have you ever taken prescription medications for high blood pressure?” 
This criteria was considered met if participants answered “yes, current use” 
† Study participants were asked “Has a doctor or other health care provider ever told you that you had 
one of the following conditions, or have you ever had one of the following procedures: 1) Diabetes 
requiring insulin? 2) Diabetes requiring tablets or pills?” This criteria was considered met if the participant 
answered “Yes” to either question. Haugnes et al19 used a similar definition, but substituted “or” for “and”. 
Neither Haugnes et al19 nor the current study measured fasting glucose. 
‡ Cutoff for non-fasting measurements based on joint consensus statement of European Atherosclerosis 
Society and European Federation of Clinical Chemistry and Laboratory Medicine.39 
§ Study participants were asked “Have you ever taken prescription medications for high cholesterol?”. 
This criteria was considered met if participants answered “yes, current use”. This may have included 
statins, fibrates and/or nicotinic acid. 
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Table 2: Clinical and Sociodemographic Characteristics of 486 Survivors of Testicular Cancer and 
Other Malignant Germ Cell Tumors at Clinical Evaluation 
Characteristic All patients 
N (%) 
Metabolic Syndrome 
P-value* Present 
N (%) 
Absent 
N (%) 
Total 486 (100%) 102 (100%) 384 (100%)  
Clinical Characteristics 
Age at diagnosis, years 
Median [range] 30.3 [15.4-49.9] 35.2 [15.7-49.7] 29.7 [15.4-49.9] <.001 
<30 229 (47.1) 32 (31.4) 197 (51.3)  
30-39 159 (32.7) 39 (20.6) 120 (31.3)  
40-49 98 (20.2) 31 (30.4%) 67 (17.4)  
Age at clinical evaluation, years 
Median [range] 38.1 [18.7-68.4] 44.4 [20.8-68.4] 36.6 [18.7-68.1] <.001 
<30 101 (20.8) 9 (8.8) 92 (24.0)  
30-39 168 (34.6) 24 (23.5) 144 (37.5)  
40-49 138 (28.4) 40 (39.2) 98 (25.5)  
≥50 79 (16.3) 29 (28.4) 50 (13.0)  
Histologic type 
Seminoma 128 (26.3) 34 (33.3) 94 (24.5) .07 
Nonseminoma† 358 (73.7) 68 (66.7) 290 (75.5)  
Site 
Testis‡ 433 (89.1) 89 (87.3) 344 (89.6) .48 
Extragonadal 53 (10.9) 13 (12.7) 40 (10.4)  
Platinum-based chemotherapy 
BEP 266 (54.7) 62 (60.8) 204 (53.1) .20 
EP 161 (33.1) 26 (25.5) 135 (35.2)  
Other§ 59 (12.1) 14 (13.7) 45 (11.7)  
Cumulative dose of cisplatin, mg/m2 
Median [range] 400 [198-800] 400 [200-600] 400 [198-800] .16 
<300 28 (5.8) 10 (9.8) 18 (4.7) .33 
300 152 (31.3) 34 (33.3) 118 (30.7)  
301-399 17 (3.5) 3 (2.9) 14 (3.6)  
400 264 (54.3) 50 (49.0) 214 (55.7)  
>400 22 (4.5) 5 (4.9) 17 (4.4)  
Otherǁ 3 (0.6) 0 3 (0.8)  
Cumulative dose of bleomycin, IU 
0 200 (41.2) 34 (33.3) 166 (43.2) .17 
>0-180,000 36 (7.4) 12 (11.8) 24 (6.3)  
181,000-270,000 178 (36.6) 38 (37.3) 140 (36.5)  
271,000-360,000 71 (14.6) 18 (17.6) 53 (13.8)  
>360,000 1 (0.2) 0 1 (0.3)  
Sociodemographic Characteristic 
Race 
White 414 (85.2) 94 (92.2) 320 (83.3) .05 
Non-white¶ 72 (14.8) 8 (7.8) 64 (16.7)  
Marital status 
Not married# 195 (40.1) 31 (30.4) 164 (42.7) .022 
Married/Living as married 291 (59.9) 71 (69.6) 220 (57.3)  
Education 
Less than college graduate 169 (34.8) 47 (46.1) 122 (31.8) .006 
 31 
College graduate or more 309 (63.6) 53 (52.0) 256 (66.7)  
Other/unknown/prefer not to 
say 
8 (1.6) 2 (2.0) 6 (1.6)  
Employment status 
Not employed 54 (11.1) 15 (14.7) 39 (10.2) .19 
Employed 432 (88.9) 87 (85.3) 345 (89.8)  
Abbreviations: BEP = bleomycin, etoposide, cisplatin; EP = etoposide, cisplatin; IU = international units; 
METs = metabolic equivalents; MetS = metabolic syndrome 
 
* P-value from Wilcoxon Test for continuous variables or Chi-square for categorical variables. Missing 
values were not included in P-value calculation. Statistically significant P-values are bolded. 
† Includes 5 patients with germ cell tumor, NOS or unidentified histology (4 without MetS and 1 had 
MetS) 
‡ Includes one survivor with unknown primary tumor site who had MetS. 
§ This category includes 14 survivors (11 without MetS and 3 with MetS) treated with 
ifosfamide/etoposide/cisplatin (VIP regimen), 3 survivors treated with carboplatin (all three with no MetS), 
and 41 survivors with other chemotherapy regimens (31 with no MetS and 10 with MetS). Chemotherapy 
regimen data was not available for one survivor who is diagnosed with MetS. 
ǁ Three survivors were treated with carboplatin instead of cisplatin. 
¶ The non-white population consisted of 5 (1.0%) Black/African American; 18 (3.7%) Asian; 1 (0.2%) 
American Indian; 9 (1.9%) who identified more than one race; 24 (4.9%) other race; and 9 (1.9%) whose 
race was not stated. 
# Not married includes 157 (32.3%) TCS who were single, 30 (6.2%) survivors who were 
widowed/divorced/separated, and 8 (1.6%) who preferred not to disclose marital status. 
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Table 3: Physical Examination and Laboratory Findings of 486 Survivors of Testicular Cancer and 
Other Malignant Germ Cell Tumors at Clinical Evaluation 
Characteristic All patients 
N (%) 
Metabolic Syndrome P-value* 
Present 
N (%) 
Absent 
N (%) 
 
Total 486 (100%) 102 (100%) 384 (100%)  
Body mass index (kg/m2) 
Median [range] 27.7 [18.0-52.8] 31.2 [23.7-46.3] 26.9 [18.0-52.8] <.001 
<25 (normal) 121 (24.9) 5 (4.9) 116 (30.2)  
25-29 (overweight) 216 (44.4) 35 (34.3) 181 (47.1)  
30-39 (obese) 128 (26.3) 51 (50.0) 77 (20.1)  
≥40 (morbidly obese) 21 (4.3) 11 (10.8) 10 (2.6)  
Testosterone (ng/mL) 
Median [range] 3.7 [0.1- 4.6] 3.4 [0.1-4.6] 3.8 [0.2-3.9] <.001 
Low (≤3.0) 150 (30.9) 47 (46.1) 103 (26.8) <.001 
Normal (>3.0) 332 (68.3) 54 (52.9) 278 (72.4)  
Not available 4 (0.8) 1 (1.0) 3 (0.8)  
Luteinizing hormone (mIU/mL) 
Median [range] 7.9 [0.1-48.7] 7.8 [0.1-46.5] 8.0 [0.1-48.7] 0.32 
Normal (<9.3) 279 (57.4) 58 (56.9) 221 (57.6) .73 
Above normal range (≥9.3) 200 (41.2) 39 (38.2) 161 (41.9)  
Not available 7 (1.4) 5 (4.9) 2 (0.5)  
Creatinine (mg/dL) 
Normal (<1.3) 401 (82.5) 87 (85.3) 314 (81.8) .41 
High (≥1.3) 85 (17.5) 15 (14.7) 70 (18.2)  
sICAM-1 (ng/mL) 
Median (range) 151 [40-882] 165 [95-633] 146 [40-882] <.001 
Lowest quartile (<124) 121 (24.9) 12 (11.8) 109 (28.4)  
2nd quartile (124-151) 122 (25.1) 25 (24.5) 97 (25.3)  
3rd quartile (152-193) 122 (25.1) 32 (31.4) 90 (23.4)  
Highest quartile (>193) 121 (24.9) 33 (32.4) 88 (22.9)  
SRD5A2 rs523349 genotype, N (%) 
Wild type (VV) 196 (40.3) 40 (39.2) 156 (40.6) .61 
Variant (VL/LL)† 209 (43.0) 47 (46.1) 162 (42.2)  
Not genotyped‡ 81 (16.7) 15 (14.7) 66 (17.2)  
Abbreviations: sICAM-1 = serum soluble cell adhesion molecule-1 
 
*P-value from Wilcoxon Test for continuous variables or Chi-square for categorical variables. Missing 
values were not included in P-value calculation 
† Includes 177 TCS who are heterozygous (VL) genotype and 32 with homozygous (LL) genotype. 
‡ Samples from these patients had not been processed in time to be included in the genotyping 
performed for this study. 
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Table 4: Comparison of Metabolic Syndrome*, its Components and Selected Cardiovascular 
Disease Risk Factors among 486 Survivors of Testicular Cancer and Other Malignant Germ Cell 
Tumors with a Matched Normative Population* 
 Platinum Study 
N (%) 
NHANES 
N (%) 
P-value† 
Total  486 (100%) 486 (100%)  
Components of Metabolic Syndrome* 
Blood pressure  
Elevated or on BP medication 210 (43.2) 149 (30.7) <.001 
Normal (systolic <130 mmHg, diastolic <85 mmHg, and 
not on BP medication) 276 (56.8) 337 (69.3) 
 
Waist circumference  
≥102 cm 137 (28.2) 195 (40.1) <.001 
<102 cm 349 (71.8) 291 (59.9)  
Diagnosis of diabetes and use of medication  
Yes 19 (3.9) 21 (4.3) .75 
No 467 (96.1) 465 (95.7)  
High density lipoprotein cholesterol 
Low (<40 mg/dL) or on cholesterol medication‡ 115 (23.7) 169 (34.8) <.001 
Normal (≥40 mg/dL and not on cholesterol medication) 371 (76.3) 317 (65.2)  
Triglycerides§ 
Elevated or on cholesterol medication‡ 195 (40.1) 174 (35.8) .17 
Normal 291 (59.9) 312 (64.2)  
Metabolic Syndrome* 
Yes (≥3 components) 102 (21.0) 109 (22.4) .59 
No (<3 components) 384 (79.0) 377 (77.6)  
Number of abnormal metabolic syndrome components 
0 151 (31.1) 154 (31.7) .58 
1 142 (29.2) 120 (24.7)  
2 91 (18.7) 103 (21.2)  
3 64 (13.2) 62 (12.8)  
4 30 (6.2) 39 (8.0)  
5 8 (1.7) 8 (1.6)  
 
CVD risk factors not included in the MetS definition 
Body mass index, kg/m2  
≥25 (overweight or obese)  365 (75.1) 336 (69.1) .04 
<25 (normal)  121 (24.9) 150 (30.9)  
Total cholesterol, mg/dL 
≥240  128 (26.3) 54 (11.1) <.001 
<240 358 (73.7) 432 (88.9)  
LDL cholesterol, mg/dL 
≥160 86 (17.7) 43 (9.3) <.001 
<160 400 (82.3) 418 (90.7)  
Smoking Status    
Never smoker 273 (56.2) 248 (51.0) <.001 
Former smoker 167 (34.4) 112 (23.1)  
Current smoker 45 (9.3) 126 (25.9)  
Not stated 1 (0.2) 0 (0.0)  
Moderate-intensity physical activity (3 to <6 METs)¶    
No 27 (5.6) 280 (57.6) <.001 
Yes 456 (93.8) 206 (42.4)  
Not stated 3 (0.6) 0 (0.0)  
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Vigorous-intensity physical activity (≥6 METs)¶    
No 159 (32.7) 323 (66.5) <.001 
Yes 324 (66.7) 163 (33.5)  
Not stated 3 (0.6) 0 (0.0)  
Abbreviations: BP = blood pressure; CVD = cardiovascular disease; LDL = low-density lipoprotein; MetS 
= metabolic syndrome; NHANES = National Health and Nutrition Examination Survey 
 
* Please refer to Methods for definition of MetS. Controls were 1:1 age-, race- and educational level-
matched males from the National Health and Nutrition Examination Survey (NHANES). 
† P-values obtained from Pearson chi-square test. 
‡ Patients were asked if they had ever taken prescription medications for high cholesterol. These may 
have included statins, fibrates and/or nicotinic acid. 
§ Cut-off points for elevated triglycerides are 150 mg/dL for those who had fasted for 8 hours or more and 
175 mg/dL for those who had less than 8 hours of fasting prior to blood sample collection.39 
ǁ 25 participants in the NHANES cohort had missing data on LDL cholesterol. 
¶ The vigorous-intensity and moderate-intensity physical activity groups are not mutually exclusive. There 
are a total of 9 different activities surveyed in the Platinum Study, some of which are moderate-intensity 
activities and some of which are vigorous-intensity activities. If a subject reported that he spent one hour 
walking a week (i.e. a moderate-intensity activity) and 30 minutes running per week (i.e. a vigorous-
intensity activity), he was included as a yes for both “any moderate” and “any vigorous” activity.23,24 Three 
survivors did not provide data on physical activity. 
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Table 5: Univariate Analyses of Potential Risk Factors for Metabolic Syndrome in Survivors of 
Testicular Cancer and Other Malignant Germ Cell Tumors 
Variable 
Metabolic Syndrome 
(Present vs. Absent) 
OR (95% CI) 
P-value 
 
Clinical Characteristic 
Age at diagnosis, per 10 years 1.66 (1.28, 2.15) <.001 
Age at clinical evaluation, per 10 years 1.99 (1.57, 2.53) <.001 
Cumulative dose of cisplatin, per 100 mg/m2 0.78 (0.56, 1.09) .15 
Cumulative dose of bleomycin, per 90,000 IU 0.99 (0.95, 1.03) .62 
 
Sociodemographic Characteristic 
Race   
White 2.13 (0.98, 4.62) .06 
Non-white Ref  
Marital status   
Married/living as married 1.98 (1.17, 3.34) .011* 
Widowed/divorced/separated 1.87 (0.72, 4.87) .20 
Single* Ref  
Education   
Less than college graduate 1.86 (1.19, 2.91) .007 
At least college graduate Ref  
Employment   
Employed 0.64 (0.32, 1.27) .20 
Not employed Ref  
 
Laboratory Finding 
Testosterone (ng/mL)   
Low (≤3.0) 2.35 (1.5, 3.69) <.001 
Normal (>3.0) Ref  
LH   
Above normal range (≥9.3) 0.92 (0.59, 1.45) .73 
Normal (<9.3) Ref  
Creatinine   
High (≥1.3) 0.77 (0.42, 1.42) .41 
Normal (<1.3) Ref  
sICAM-1 Quartile (ng/mL)   
Lowest quartile (<123.53) Ref  
2nd quartile (123.53-150.74) 2.34 (1.12, 4.91) .024 
3rd quartile (151.64-192.77) 3.23 (1.57, 6.63) .001 
Highest quartile (>192.77) 3.41 (1.66, 6.98) .001 
 
Health Behavior 
Smoking Status   
Former smoker 1.13 (0.71, 1.80) .62 
Current smoker 1.13 (0.53, 2.43) .75 
Never smoker Ref  
Alcohol Use   
≤4 per week 0.77 (0.44, 1.32) .34 
5 per week to 1 daily 0.36 (0.17, 0.74) .006 
≥2 daily 0.76 (0.36, 1.62) .48 
Rarely or never Ref  
 36 
Physical activity intensity   
Moderate (3 to <6 METs)    
Yes 1.17 (0.43, 3.18) .75 
No Ref  
Vigorous (≥6 METs)   
Yes 0.45 (0.29, 0.71) .001 
No Ref  
Abbreviations: CI = confidence interval; LH = luteinizing hormone; METs = metabolic equivalents; sICAM-
1 = serum soluble cell adhesion molecule-1 
 
* The apparent protective effect of single status is likely due to these participants being younger. The 
correlation is not significant when marital status is adjusted for age at clinical evaluation. 
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Table 6: Multinomial Logistic Regression Analyses of Potential Correlates with Metabolic 
Syndrome in Survivors of Testicular Cancer and Other Malignant Germ Cell Tumors* 
Clinical Factor OR 95% CI P-value 
 
Clinical and Sociodemographic Characteristics 
Age at clinical evaluation, per 10 years  1.75 1.33-2.30 <.001 
Education    
Not college graduate 1.51 0.91-2.51 .11 
College or post graduate - - Ref 
Marital status    
Not married 0.88 0.51-1.49 .62 
Married/living as married - - Ref 
 
Laboratory Findings 
Serum testosterone (ng/mL)    
Low (≤3.0) 2.06 1.25-3.39 .005 
Normal (>3.0) - - Ref 
sICAM-1 (ng/mL)    
Lowest quartile (<124) - - Ref 
2nd quartile (124-151) 2.73 1.24-6.06 .01 
3rd quartile (152-193) 3.21 1.48-6.95 .003 
Highest quartile (>193) 3.58 1.66-7.75 .001 
 
Health Behaviors 
Average number of alcoholic drinks in past year    
≤4 per week 0.85 0.46-1.56 .60 
5 per week to 1 daily 0.47 0.21-1.05 .07 
≥2 daily 0.73 0.31-1.69 .46 
Rarely or never - - Ref 
Vigorous intensity physical activity (≥ 6 METs)    
Yes  0.84 0.49-1.44 .53 
No - - Ref 
Abbreviations: CI = confidence interval; METs = metabolic equivalents; OR = odds ratios; Ref = 
reference; sICAM-1 = serum soluble cell adhesion molecule-1; Bold indicates ORs with P<.05 
* For the multinomial logistic regression analyses, 18 survivors were excluded due to unavailable data for 
one or more variables. 
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Table 7: Comparison of Prevalence of Metabolic Syndrome (MetS) in Genotype Groups for SNP 
rs523349 (V89L) in SRD5A2 Gene between TCS in Boer et al20 and in the Platinum Study 
 Boer et al (n= 173) Platinum Study (n= 405) 
 Wild type (VV) 
(n= 91, 52.6%) 
Variant (VL/LL) 
(n= 82, 47.4%)* 
P-value Wild type (VV) 
(n= 196, 48.4%) 
Variant (VL/LL) 
(n= 209, 51.6%)† 
P-value 
MetS‡ (%): 
all survivors 19% 33% .03 20% 22% .61 
MetS (%): 
testosterone 
<4.3 ng/mL 
33% 67% Not reported 26% 25% .98 
MetS (%): 
testosterone 
≥4.3 ng/mL 
17% 20% Not reported 16% 19% .60 
Abbreviations: MetS = metabolic syndrome; SNP = single nucleotide polymorphism; TCS = testicular 
cancer survivors 
 
* 64 TCS with heterozygous (VL) genotype and 18 with homozygous (LL) genotype.  
† 177 TCS with heterozygous (VL) genotype and 32 with homozygous (LL) genotype. 
‡ For assessment of the metabolic syndrome, Boer et al. used the American Heart Association/National 
Heart Lung Blood Institute (AHA/NHLBI) classification67 with the metabolic syndrome diagnosed if three 
or more of the following criteria were present: central obesity (waist circumference ≥102 cm), high 
triglycerides (≥1.7 mmol/L [≥150 mg/dL] or on medication), low high-density lipoprotein (HDL) cholesterol 
(<1.03 mmol/L [<40 mg/dL] or on medication), high blood pressure (systolic ≥130 mmHg or diastolic ≥85 
mmHg or on medication), and high glucose (≥5.6 mmol/L [100 mg/dL] or on medication). 
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Table 8: Prevalence of Metabolic Syndrome (MetS), Component Criteria, and Related Variables in Studies of Testicular Cancer Survivors (TCS) 
 Haugnes et al (2007)
19 
Norway 
Wethal et al (2007)16 
Norway 
de Haas et al (2012)17 
Netherlands (Groningen) 
Willemse et al (2013)18 
Netherlands (Leiden) 
Number of patients 
Chemotherapy (BEP, 
PVB, other)* 
Surger
y only† 
Healthy 
controls‡ 
Chemotherapy 
(BEP, PVB)§ 
Surgery 
onlyǁ 
Chemotherapy (BEP, EP, 
other)¶ 
Chemotherapy 
(BEP, other)# 
Surgery 
only** 
Healthy 
controls
†† 
Cis 
≤850 mg 
Cis 
>850 mg         
376 88 225 1150 218 140 173 176 58 360 
Clinical and demographic characteristics 
Median age at TC 
diagnosis, years (range) 
29  
(15-52) 
26  
(15-48) 
29 
 (16-53) -- 
28 
(23-34) 
29 
(24-35) 
28 
(16-25)‡‡ 
31.2 
(14.2-54.2) 
30.4 
(20.0-61.9) -- 
Median age at follow-up, 
years (range) 
42 
(23-60) 
36 
(25-59) 
41 
(24-60) 
48 
(30-60) 
41 
(34-46) 
40 
(36-47) 
37 
(19-59) 
38.7 
(18.2-63.4) 
36.6 
(20.1-69.5) 
43.1 
(18-70) 
Median follow-up, years 
(range) 
11.8 
(5-22) 
9.4 
(5-20) 
11.8 
(5-21) n/a 
12 
(8-15) 
11 
(7-15) 
5 
(3-20) 
8.8 
 (0.6-30.2) 
6.2 
(0.1-2) n/a 
Calendar years of 
therapy 1980-1994 n/a 1980-1994 1977-2004 n/a n/a n/a 
Smoking status (%)           
Never smoker 144 (41) 48 (58) 89 (42) 370 (33) n/a n/a 72 (42) n/a§§ n/a§§ n/a§§ 
Ever smoker 207 (55) 35 (40) 123 (55) 734 (64) n/a n/a 100 (58) n/a
§§ n/a§§ n/a§§ 
Current non-smoker n/a n/a n/a n/a 122 (61.3) 71 (62.8) 107 (62) n/a§§ n/a§§ n/a§§ 
Current smoker n/a n/a n/a n/a 77 (38.7)ǁǁ 42 (37.2)ǁǁ 65 (38) n/a§§ n/a§§ n/a§§ 
Prevalence of MetS, components included in definition, and related variables, N(%)¶¶ 
Metabolic syndrome## 149 (40) 42 (48)*** 72 (33) 584 (51) –††† (17.6) –††† (6.3) 44 (25) 29 (16.7)‡‡‡ 5 (8.8)‡‡‡ 29 (8.1) 
Hypertension 166 (45)*** 42 (48)*** 77 (34) 568 (50) n/a n/a 100 (59) 53 (31.0)*** 8 (14.0) 81 (22.5) 
Obesity§§§ 60 (16)ǁǁǁ 23 (26)*** 28 (13) 237 (21) n/a n/a 29 (17) 51 (29.3) 10 (17.5) 70 (19.4) 
Hypercholesterolemia 246 (67) 63 (73) 151 (67) 963 (84) n/a n/a n/a n/a n/a n/a 
Dyslipidemia (Low HDL 
or statin usage) n/a n/a n/a n/a n/a n/a n/a 35 (20.1) 7 (12.3) 36 (10.0) 
Elevated triglycerides n/a n/a n/a n/a n/a n/a 50 (29) 61 (35.1) 13 (22.8) 84 (23.3) 
Insulin resistance n/a n/a n/a n/a n/a n/a n/a 11 (6.3) 2 (3.5) 16 (4.4) 
Diabetes¶¶¶ 11 (2.9) 2 (2.3) 4 (1.8) 33 (2.9) 5 (2.5) 2 (1.6%) n/a n/a n/a n/a 
Age-adjusted OR (95% CI) for MetS 
Survivors vs. healthy 
controls 
1.0### 
(0.8-1.2) 1.0 n/a n/a 
2.2**** 
(1.5-3.3) 
1.9†††† 
(1.1-3.2) n/a 1.0 
Chemotherapy vs. 
surgery only 1.5
###,‡‡‡‡ 2.8
###  
(1.6-4.7) 1.0 n/a 
3.7  
(1.5-9.1) 1.0 n/a 
2.1 
(0.8-5.7) 1.0 n/a 
Chemotherapy vs. 
healthy controls n/a 
2.1### 
(1.3-3.4) n/a 1.0 n/a n/a n/a 
2.3†††† 
(1.3-4.0) n/a 1.0 
Markers of gonadal function 
 Mean (SD) Median (IQR) Median (range) Median (range) 
Testosterone (nmol/L) 15.6 (5.8) 14.8 (5.8) 
16.2 
(4.9) 
14.4 
(5.5) 
15.3 
(12.0-18.7) 
16.2 
(13.1-20.6) 
15.0§§§§ (9-31); MetS 14.1§§§§,ǁǁǁǁ 
(6.4-32.1) 
16.8 
(7.6-33.9)§§§§ n/a 18.0 (4-37); No MetS 
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Luteinizing hormone 
(IU/L) n/a n/a n/a n/a 
5.2ǁǁǁǁ 
(3.6-7.8) 
4.4 
(3.2-6.7) 
6.4 (2.5-18.7); MetS 
5.5 (1.6-33.1); No MetS 
6.8 
(0.4-48.1) 
5.9 
(0.1-36.4) n/a 
Pro-inflammatory markers¶¶¶¶ 
Leptin (ng/mL) n/a n/a n/a n/a 5.3 (3.0-9.5) 
4.8 
(2.3-9.7) 
12.8#### (2.4-43.3); MetS n/a n/a n/a 3.7 (0.2-66.1); No MetS 
hsCRP (mg/L) n/a n/a n/a n/a 1.2 (0.7-2.4) 
1.2 
(0.6-2.0) 
1.6 (0.2-13.4); MetS <3 
(<3-30) 
<3 
(<3-18) n/a 1.1 (0.2-31.8); No MetS 
Biochemical markers 
HDL (mmol/L) n/a n/a n/a n/a 1.1
ǁǁǁǁ 
(1.0-1.3) 
1.0 
(1.1-1.4) n/a 
1.4 
(0.6-4.1) 
1.3 
(0.7-2.7) 
1.3 
(0.6-2.9) 
Triglycerides (mmol/L) n/a n/a n/a n/a 1.6
ǁǁǁǁ 
(1.0-2.4) 
1.2 
(0.9-2.0 n/a 
1.3ǁǁǁǁ 
(0.3-7.4) 
1.0 
(0.4-4.3) 
1.2 
(0.4-4.3) 
Apolipoprotein A1 (g/L) n/a n/a n/a n/a 1.4 (1.3-1.5) 
1.4 
(1.3-1.6) n/a n/a n/a n/a 
Clinical variables           
Systolic blood pressure 
(mm Hg) n/a n/a n/a n/a 
125ǁǁǁǁ 
(120-140) 
120 
(115-130) n/a 
126 
(90-200) 
122 
(95-185) 
130 
(110-
200) 
Body mass index (kg/m2) n/a n/a n/a n/a 25.7 (23.8-27.9) 
26.2 
(24.3-28.6) n/a 
25.6 
(18.4-36.4) 
24.2 
(16.8-38.5) 
25.8 
(19.5-
42.6) 
Risk factors for MetS*****, Odds Ratio (95% CI; p value) 
Low serum 
testosterone††††† 
0.96  
(0.93-0.98; P=0.001) 
0.93 
(0.87-0.99; P=0.015) 
4.1 
(1.8-9.3; P=0.001) 
1.7‡‡‡‡‡ 
(0.8-3.6) 
Smoking status§§§§§ 1.48 (1.00-2.18; P=0.273) n/a n/a 
2.0‡‡‡‡‡ 
(1.0-4.0) 
Cisplatin doseǁǁǁǁǁ 3.05 (1.72-5.40; P=0.002) n/a n/a n/a 
Luteinizing hormone n/a 0.89 (0.81-0.98; P=0.021) n/a n/a 
Apolipoprotein A1 n/a 0.003 (0-0.019; P<0.001) n/a n/a 
Abbreviations: BEP = bleomycin, etoposide, cisplatin; BOP/VIP = bleomycin, vincristine, cisplatin/etoposide, ifosfamide, and cisplatin; CEB = carboplatin, etoposide, and 
bleomycin; CI = confidence interval; Cis = cisplatin; EP, etoposide, cisplatin; HDL = high-density lipoprotein; hsCRP = high-sensitivity C-reactive protein; IQR = interquartile 
range; LH = luteinizing hormone; MetS = metabolic syndrome; n/a = not available; OR = odds ratio; PVB = cisplatin, vinblastine, bleomycin; PVB/BEP = alternating courses of 
PVB and BEP; SD = standard deviation; TC = testicular cancer; TCS = testicular cancer survivors 
* Most patients received cisplatin-based chemotherapy (n=442, 95%), primarily in combination with etoposide and bleomycin or vinblastine and bleomycin. The number of 
patients or number of chemotherapy cycles in each treatment group was not provided. A subgroup (n=22, 5%) received carboplatin instead of cisplatin and were included in 
the Cis ≤850mg group, as MetS risk did not differ from those who received cisplatin-based chemotherapy. Additionally, 66% (n=304) of all chemotherapy-treated patients 
underwent retroperitoneal surgery and 10% (n=47) received additional radiotherapy (primarily infradiaphragmatic). 
† Patients either underwent retroperitoneal surgery (n=124) or had been included in a surveillance program after orchiectomy without subsequent relapse. No patient received 
radiotherapy or chemotherapy. 
‡ Haugnes et al selected healthy controls from the Tromsø Study,68 a population-based study conducted during the same time period as the TCS follow-up study, but excluded 
individuals 60 years or older or treated with testosterone substitution. 
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§ Treatment included cisplatin in combination with bleomycin, vinblastine (before 1985) or etoposide (post 1985), with or without surgery. Numbers of patients in each 
treatment category were not provided. 
ǁ Patients either underwent retroperitoneal lymph node dissection or were under surveillance after orchiectomy. 
¶ Most patients received BEP or EP (n=159, 92%). The number of cycles of chemotherapy in each treatment group was not provided; neither were the number of patients. One 
patient (1%) received alternating BEP and PVB, while 13 patients (7%) received ‘other’ regimens that included CEB (carboplatin, etoposide and bleomycin) or BOP/VIP 
(bleomycin, vincristine, cisplatin/etoposide, ifosfamide, and cisplatin). 
# All patients were diagnosed with disseminated TC and treated with orchiectomy and combination chemotherapy, primarily consisting of BEP (99%), with a median cisplatin 
dose of 604 (0-1750) mg. The number of treatment cycles was not provided. Two patients received carboplatin instead of cisplatin.  
** Patients were diagnosed with Stage I disease and treated with orchiectomy alone. 
†† Healthy controls consisted of men from the general population, living in the same geographical area, who had participated in a 2009 cardiovascular disease screening 
program; data were obtained from general practitioners’ health screening records. 
‡‡ Age at treatment 
§§ Authors indicated that smoking behavior was comparable in all groups of patients and controls (smoker prevalence ~40%), but did not present numbers or percentages for 
each smoking status category, or clarify whether “smoker” was defined as “current smoker” or “ever smoker”. 
ǁǁ Smoking data missing for 27 patients in the surgery group and 19 patients in the chemotherapy group. 
¶¶ Haugnes and Wethal collected data on prevalence of diabetes. Haugnes reported Type 2 diabetes in 33 (2.9%) healthy controls, 4 (1.8%) TCS treated with surgery only, 11 
(2.9%) TCS treated with Cis ≤850mg, and 2 (2.3%) TCS treated with Cis >850mg. Wethal reported Type 1 or Type 2 diabetes in 2 (1.6%) TCS treated with surgery only and 5 
(2.5%) TCS treated with chemotherapy. 
## Studies used different criteria to define MetS. 1) Haugnes et al modified the National Cholesterol Education Program Adult Treatment Panel (NCEP-ATP III)69 definition so 
that MetS was present when a patient met ≥2 of the following criteria: hypertension (BP ≥140/90 mmHg or medication), obesity (BMI ≥30 kg/m2), diabetes (self-reported 
diabetes or use of diabetes medication), or hypercholesterolemia (serum total cholesterol ≥5.2 mmol/l (≥200 mg/dL) or medication). 2) Wethal et al modified the NCEP-ATP 
III70 definition so that MetS was present when a patient met ≥3 of the following criteria: hypertension (systolic BP ≥130 mm Hg or diastolic BP ≥85 mmHg, or medication), 
hypertriglyceridemia (serum triglycerides ≥1.70 mmol/L), dyslipidemia (HDL<1.04 mmol/L), or obesity (BMI ≥30 kg/m2). Wethal excluded use of serum glucose measurements 
because subjects were non-fasting and also excluded a history of diabetes (n=15). 3) de Haas et al used the American Heart Association/National Heart, Lung, and Blood 
Institute classification,67 which defines MetS as meeting ≥3 of the following criteria: central obesity (waist circumference ≥102 cm), hypertriglyceridemia (≥1.7 mmol/L or 
medication), dyslipidemia (HDL <1.03 mmol/L or medication), hypertension (systolic ≥130 mmHg or diastolic ≥85 mmHg or medication), or hyperglycemia (≥5.6 mmol/L or 
medication). 4) Willemse et al classified MetS by using two different guidelines. For consistency among studies presented in this table, we selected results derived from their 
application of the NCEP-ATPIII definition,69 i.e., MetS is present when ≥3 of the following criteria are met: hypertension (systolic BP ≥135 mmHg and diastolic BP ≥85 mmHg), 
obesity (waist circumference ≥102 cm), insulin resistance (fasting glucose ≥6.1 mmol/L (110 mg/dL), dyslipidemia (HDL-cholesterol <1.03 mmol/L (40 mg/dL) or statin usage), 
or hypertriglyceridemia (serum triglycerides ≥1.7 mmol/L (150 mg/dL)). 
*** P<0.05 between compared to surgery group 
††† Number of patients not provided. 
‡‡‡ Three TCS were diagnosed with diabetes mellitus before orchiectomy (n=1) or combination CT (n=2) and were excluded from these analyses, thus, prevalence estimates 
are based on a total of 57 surgery patients and 174 chemotherapy patients.  
§§§ Obesity was defined as BMI ≥30 kg/m2 (Haugnes et al) or waist circumference ≥102 cm (de Haas et al; Willemse et al). 
ǁǁǁ P<0.05 between compared to cisplatin >850 mg group. 
¶¶¶ Haugnes et al included subjects with Type 2 diabetes. Wethal et al included subjects with Type 1 and Type 2 diabetes. Willemse et al indicated that five subjects developed 
diabetes during follow-up period, but did not specify their treatment group(s). 
### Adjustment for total testosterone did not significantly change any of the results. 
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**** Healthy controls consisted of 1,085 men (1,020 from the Retention of Renal and Vascular End-stage Disease (PREVEND) study71,72 and 65 from the sibling controls 
participating in a childhood cancer survivor study (CCS)73) with data on waist circumference, blood pressure, fasting lipid and glucose levels, and medication use. Median age 
was 44 years (range 18-55). 
†††† Smoking-adjusted risk of MetS for all TCS was 1.8 (95% CI, 1.1-3.1) compared to healthy controls, and for TCS treated with chemotherapy the risk was 1.5 (95% CI, 1.1-
2.0) compared to healthy controls. 
‡‡‡‡ OR was obtained from a figure where no numerical values were provided for the corresponding 95% CI or P-value. 
§§§§ 34 TCS (1 surgery and 33 combination-CT) had serum testosterone levels <104 µmol/L. 
ǁǁǁǁ P<0.05 between surgery and chemotherapy groups 
¶¶¶¶ Wethal et al also measured von Willebrand factor (%) in TCS who received chemotherapy (14.7; 11.9-18.9) or surgery alone (15.0; 10.7-18.8); P=0.63. de Haas et al also 
measured the following serum proinflammatory markers in TCS who received chemotherapy (median; range): 1) von Willebrand factor (%) in patients with MetS (98; 28-220) 
vs. those without MetS (96; 37-296); P=0.516. 2) adiponectin (µg/mL) in patients with MetS (5.00; 2.04-11.19) vs. those without MetS (7.23; 2.76-17.40); P<0.0001. 3) 
Fibrinogen (g/L) in patients with MetS (3.2; 1.5-5.0) vs. those without MetS (2.8; 1.2-6.3); p=0.038. 4) Tissue plasminogen activator (ng/mL) in patients with MetS (11.0; 3.7-
21.0) vs. those without MetS (6.5; 1.5-21.0); P<0.0001. 5) Plasminogen activator inhibitor-1 (ng/mL) in patients with MetS (57.0; 7.8-312.0) vs. those without MetS (19.0; 3.0-
62.0); P<0.0001. 6) Ratio of plasminogen activator inhibitor-1 to tissue plasminogen activator in patients with MetS (5.4; 1.5-31.6) vs. those without MetS (3.2; 0.5-7.1); 
P<0.0001. 
#### P<0.0001 between chemotherapy patients categorized with MetS versus those without MetS. 
***** All results derive from logistic regression models that used data only from TCS and designated MetS as the dependent variable. The Haugnes et al model adjusted for 
treatment group (referent: surgery), total testosterone (continuous), pack-years (referent: never smoker), physical activity (referent: no activity), educational level (referent: 
low), family status (referent: living alone), and age (continuous). The Wethal et al model adjusted for treatment group (referent: surgery), testosterone (continuous), LH 
(continuous), Apo-A1 (continuous), and age (continuous). The de Haas et al model only included adjustment for age. Willemse et al did not specify whether, if any, other 
variables were included in the model. 
††††† Haugnes et al and Wethal et al treated testosterone as a continuous variable and found increased risk for MetS in TCS with low testosterone. de Haas et al and Willemse 
et al treated total testosterone as a categorical variable. Willemse et al found an increased risk of MetS in TCS with serum testosterone in the lowest quartile (<12.0 nmol/L), 
as compared with the upper 3 quartiles. de Haas et al found an increased risk for MetS in TCS with total testosterone <15 nmol/l, as compared with ≥15 nmol/L. 
‡‡‡‡‡ P-value not provided. 
§§§§§ Haugnes et al found an increased risk of MetS in TCS who smoked ≥20 pack-years, as compared with never smokers. Willemse et al found an increased risk of MetS in 
TCS who smoked, as compared with non-smokers. Willemse et al also found an increased risk of MetS in healthy controls who smoked, as compared with non-smokers: OR 
1.6 (95% CI 0.7-3.4). 
ǁǁǁǁǁ Risk for MetS in TCS receiving a cisplatin dose >850 mg, as compared with TCS in the surgery group. 
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